Theratechnologies

Theratechnologies is a Canadian biopharmaceutical company listed on the Toronto Stock Exchange for over 10 years. The Company has a promising portfolio of products at various stages of development. To maximize its long term value, Theratechnologies develops novel therapeutic products in order to bring them to market.  

The company's lead product, TH9507, a growth hormone-releasing factor analogue, is currently in Phase 3 clinical development in HIV-associated lipodystrophy.  In addition, the company is exploring further development of TH9507 for applications in other indications.  Growth hormone deficiency in adults and management of cystic fibrosis are among the indications currently being considered by the Company. 

The company is actively developing other innovative therapeutic products, that are at earlier development stages, the most advanced of which targets acute renal failure. Using their proprietary discovery technologies, their team of scientists have developed several compounds that could feed their product portfolio over the coming years. Finally, the Company has several therapeutic products targeting type 2 diabetes, glaucoma and premature labour intended for out-licensing.

SGF participation: 5%

www.theratech.com